News archive

American Academy of Neurology / Neurology · 16 Oct 2026 · Research

In one US region, first strokes at ages 20 to 54 rose from 33.9 to 62.2 per 100,000 between 1993 and 2020

Study (population surveillance, one region). Emily R. Fisher at the University of Cincinnati and colleagues report in Neurology, published 23 Sep 2026 (DOI 10.1212/WNL.0000000000218622), on Greater Cincinnati and Northern Kentucky. They counted 2,076 first strokes in adults ages 20 to 54 from 1993 to 2020. The rate rose from 33.9 to 62.2 cases per 100,000 person-years, about an 83 percent increase. Ischemic stroke, a blocked vessel, rose from 23.8 to 47.3 and accounted for most of the change. Bleeding strokes did not show a comparable rise. Among people who had a stroke, high blood pressure, diabetes, atrial fibrillation, and substance use became more common; documented substance use rose from 4.6 percent to 40.2 percent, much of it cannabis. There was no comparison group without stroke, so the paper cannot show that those factors caused the rise. Thirty-day death fell from 11.7 percent to 9.4 percent after accounting for age, race, and sex. The pattern is local, not a national rate. Not medical advice.

Read at American Academy of Neurology / Neurology →♡ Save

• Under 40
• 40–59
• Cardiovascular / lipids
• Metabolic / glucose

• stroke
• ischemic
• surveillance
• study

Cedars-Sinai / Cell Metabolism · 16 Oct 2026 · Aging

In aging mice, blocking PD-L2 cut the buildup of senescent cells and improved glucose handling

Study (mice, plus human cells and tissue). Selim Chaib, James Kirkland, and colleagues at Cedars-Sinai report in Cell Metabolism (DOI 10.1016/j.cmet.2026.08.014) that the surface marker PD-L2 may help senescent cells avoid immune clearance. In laboratory mice, removing or blocking PD-L2 reduced the buildup of those cells, lowered inflammatory signals, improved glucose handling, and produced a firmer hand grip. Senescent human cells made more PD-L2 than younger cells, and the marker rose with age in some human tissues. This is not a treatment for people. Some authors hold related patents, including licenses to a senescence company. Not medical advice.

Read at Cedars-Sinai / Cell Metabolism →♡ Save

• Metabolic / glucose

• senescence
• immune
• glucose
• inflammation
• study

Rutgers / Annals of Internal Medicine · 16 Oct 2026 · Supplements / medicine

In adults ages 18 to 65 with type 2 diabetes, GLP-1 medicines lined up with about 3 to 4 extra optic-nerve injury cases per 10,000

Study (records comparison, not a trial). Chintan Dave and colleagues at Rutgers report in Annals of Internal Medicine (DOI 10.7326/ANNALS-25-00860) on US adults ages 18 to 65 with type 2 diabetes who had recently started a glucose-lowering medicine. GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), lined up with about three to four additional ischemic optic neuropathy cases per 10,000 people over 18 months. The injury can cause sudden vision loss; about one third of patients regain some sight, usually in the first six months, and some loss often remains. Cases clustered in men and in ages 50 to 65. The authors say this is not proof the medicines caused the injury. It is not a reason to start or stop a prescription. Sudden vision changes need a clinician promptly. Not medical advice. Not a substitute for a prescribed medicine. Off-label use is clinician-only. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Read at Rutgers / Annals of Internal Medicine →♡ Save

• Under 40
• 40–59
• 60+
• Metabolic / glucose

• glp1
• vision
• type-2
• study
• off-label-context

Charité Berlin / Radiology · 16 Oct 2026 · Research

In 194 people with knee osteoarthritis, median age 69, dissolving-particle embolization cut median pain from 7 to 3 at one year

Study (single-center series, no sham arm). Florian Nima Fleckenstein and colleagues at Charité in Berlin report in Radiology (DOI 10.1148/radiol.253312) on 194 people, 114 women and 80 men, median age 69, median body mass index 28.4. All still had pain after at least three months of therapy, pills, and joint injections. Genicular artery embolization with gelatin microspheres that dissolve within hours was technically successful in 239 procedures. Median pain on a 0-to-10 scale fell from 7 to 4 at six weeks and to 3 at six and 12 months. Of those assessed at one year, 80 percent cleared a 2-point pain threshold. Mild temporary complications occurred in 6.7 percent of procedures. No moderate or severe events were recorded. A separate 2026 sham-controlled trial of 58 people found no significant pain gap between embolization and a sham procedure, and a pooled look at three randomized trials found no significant advantage over sham. This series cannot show how much of the change was the procedure itself. Not medical advice.

Read at Charité Berlin / Radiology →♡ Save

• Women
• Men
• 60+

• osteoarthritis
• embolization
• pain
• study

BMJ Oncology · 16 Oct 2026 · Research

In England, bowel and ovarian cancer rose in adults under 50, and that rise was not seen at age 50 and above

Study (registry trends, 2001 to 2019). Montserrat Garcia-Closas and colleagues report in BMJ Oncology (DOI 10.1136/bmjonc-2025-000966) using England's National Disease Registry Service. They compared more than 20 cancer types in men and women ages 20 to 49 with adults age 50 and above. Among younger women, 16 of 22 cancer types rose. Among younger men, 11 of 21 rose. Bowel and ovarian cancer rose under 50 and did not show the same rise at age 50 and above. Endometrial, kidney, pancreatic, thyroid, and multiple myeloma rose faster in younger women than in adults age 50 and above. In men, only multiple myeloma rose significantly faster in the younger group. Excess body weight was tied to 10 of 11 highlighted cancers, but both weight-related and non-weight rates rose. The work is observational, limited to England, and assumes about a 10-year lag from exposure to diagnosis. Absolute numbers remain higher at age 50 and above. Not a screening recommendation. Not medical advice.

Read at BMJ Oncology →♡ Save

• Women
• Men
• Under 40
• 40–59

• cancer
• incidence
• england
• study

Arizona State University / PLOS One · 16 Oct 2026 · Nutrition

A 2026 digestion model, checked against a feeding study, estimated about 116 fewer calories absorbed per day on a higher-fiber pattern

Study (mathematical model checked against an earlier feeding trial). Taylor Davis, Rosa Krajmalnik-Brown, Bruce Rittmann, and colleagues at Arizona State University describe a digestion, absorption, and microbial metabolism model in PLOS One (2026; DOI 10.1371/journal.pone.0347668). They compared it with a controlled feeding study of healthy adults. One pattern was high in fiber and resistant starch, with larger particle size. The other resembled a usual Western pattern, lower in fiber. People on the Western pattern absorbed about 116 more calories per day. The higher-fiber group did not report more hunger. The model estimated that short-chain fatty acids from the colon supplied about 140 calories a day, about 7.4 percent of usable energy, and that about 85 percent of usable energy came from the upper gut and about 15 percent from the lower gut. Standard label math underestimated absorbed calories. This is a research framework, not a personal meal plan. Not medical advice.

Read at Arizona State University / PLOS One →♡ Save

• fiber
• microbiome
• calories
• gut
• study
• commentary

Texas A&M / Journal of the International Society of Sports Nutrition · 16 Oct 2026 · Supplements / medicine

In 64 adults ages 45 to 65, daily creatine lined up with more lean tissue even without a structured training plan

Study (12 weeks; people chose whether to join a training plan, then were randomized to creatine or placebo). Richard Kreider and colleagues at Texas A&M report in the Journal of the International Society of Sports Nutrition (DOI 10.1080/15502783.2026.2716273). Sixty-four healthy adults ages 45 to 65 finished. The study dose was 10 grams of creatine monohydrate a day. In the group that did not join the plan, creatine lined up with about 2.4 pounds more lean tissue and higher leg-press and bench-press loads. In the group that trained and ate at a modest calorie deficit, creatine lined up with nearly 3 pounds more lean tissue and a larger drop in body-fat percentage, while the placebo group showed little lean-tissue change. Creatine did not add aerobic capacity beyond training alone. Assignment to training was not randomized. A 2025 review by the same lab of 685 trials found no significant gap in reported side-effect rates versus placebo. This is not a disease treatment, not a personal dose, and not medical advice.

Read at Texas A&M / Journal of the International Society of Sports Nutrition →♡ Save

• 40–59
• 60+

• creatine
• lean-tissue
• middle-age
• fitness
• nutrition
• study

Sanford Burnham Prebys / Aging Cell · 16 Oct 2026 · Aging

In healthy volunteers ages 23 to 72, cellular recycling during aging rose, fell, or stayed flat by cell type and sex

Study (human cells, plus a five-person pilot). Tatiana Moreno, Caroline Kumsta, and colleagues at Sanford Burnham Prebys report in Aging Cell, posted 27 Sep 2026 (DOI 10.1111/acel.70734). Volunteers ages 23 to 72 with no chronic conditions gave blood and skin samples. Recycling activity fell with age in skin cells from men, stayed about flat in skin cells from women, and rose with age in neurons made from women's skin cells. Gene readouts did not reliably match the measured recycling rate. At age 70 and above, higher recycling lined up with worse function, including a weaker hand grip, higher body mass index in the skin-cell comparison, and a higher resting heart rate in the neuron samples. A pilot of five people ages 77 to 88 used a 12-week fall-prevention movement program. Recycling in blood cells moved toward levels more typical of younger adults, and function improved. Five people cannot settle that result. Not a therapy. Not medical advice.

Read at Sanford Burnham Prebys / Aging Cell →♡ Save

• Women
• Men
• Under 40
• 40–59
• 60+

• autophagy
• cell-recycling
• sex-difference
• study

Penn Medicine / JAMA · 16 Oct 2026 · Supplements / medicine

In one man treated in his fifties, brain regions cleared of amyloid held little tau while neighboring regions did not

Case report (one brain). Christopher A. Brown, David Wolk, Edward B. Lee, and colleagues at Penn Medicine report in JAMA (DOI 10.1001/jama.2026.13058). The man was diagnosed in his fifties with mild cognitive impairment from Alzheimer disease, then received 30 doses of aducanumab over four and a half years. He died about four years after the last dose. On the raised ridges of the cortex, amyloid plaques were largely gone and tau tangles were scarce. In the neighboring grooves, amyloid remained and tau, inflammation, and tissue loss were much heavier. Scans during life had already shown uneven clearance. Aducanumab is no longer sold. Newer amyloid antibodies use a related approach, but this single case cannot prove that clearance caused the tau difference or name a dose that protects people. Not medical advice.

Read at Penn Medicine / JAMA →♡ Save

• Men
• 40–59
• Cognitive / dementia research

• alzheimer
• amyloid
• tau
• cognition
• inflammation

British Journal of Sports Medicine · 16 Oct 2026 · Supplements / medicine

Across 147,374 health workers followed up to 30 years, 90 to 119 minutes a week of resistance work lined up with a 13 percent lower death rate

Study (observational, repeated questionnaires). Zhang, Lee, Rezende, Ma, and Giovannucci report in the British Journal of Sports Medicine (2026; 60:874; DOI 10.1136/bjsports-2025-110503). The Nurses' Health Study, the Nurses' Health Study II, and the Health Professionals Follow-up Study included 31,540 men and 115,834 women and recorded 35,798 deaths over up to 30 years. Versus no resistance work, 90 to 119 minutes a week lined up with a hazard ratio of 0.87 for death from any cause (95 percent CI 0.81 to 0.95), 0.81 for cardiovascular death, and 0.73 for neurological-disease death, after accounting for aerobic activity. Above 120 minutes a week the death-rate link did not keep growing. Cancer death was lower only at 1 to 29 minutes (0.91) and 30 to 59 minutes (0.88). People with higher aerobic activity plus 60 to 119 minutes of resistance work had a hazard ratio of about 0.55 versus low aerobic activity and no resistance work. Habits were self-reported. This is not proof that lifting caused longer life. Not medical advice.

Read at British Journal of Sports Medicine →♡ Save

• Women
• Men
• 40–59
• 60+
• Cardiovascular / lipids

• resistance
• mortality
• cohort
• fitness
• study

The Menopause Society · 14 Oct 2026 · Research

In a survey of more than 1,800 app users, more frequent activity lined up with a lower perimenopause symptom score

Meeting presentation, not a journal paper. The Menopause Society said on 14 Oct 2026 that a Flo Health analysis will be presented 20–24 Oct 2026 in San Diego. More than 1,800 respondents in 87 countries reported activity from none to more than five days a week and completed a Menopause Rating Scale. In the unadjusted comparison, higher activity frequency lined up with lower total scores across somatic, psychological, and urogenital domains. The presenting author said the pattern looked strongest for low mood, irritability, and anxiety. Age, body mass index, smoking, other illnesses, healthcare access, and a country development index were planned as confounders; the release does not give the adjusted numbers. Self-report from an app is not a trial. Not medical advice.

Read at The Menopause Society →♡ Save

• Women
• 40–59

• perimenopause
• activity
• study

Nature Aging · 14 Oct 2026 · Nutrition

In aged mice, raising the RNA-processing gene SRSF1 in the liver extended median lifespan by 14 percent

Study (cells and mice). A Wyss Institute team led by George Church and Alex Plesa, with Sascha Jung and Antonio del Sol, report in Nature Aging on 14 Oct 2026. A gene-expression age score trained on 464 human skin-fibroblast samples ranked the RNA-processing gene SRSF1 at the top of an overexpression screen. In old fibroblast lines, SRSF1 shifted senescence, protein-stress, and inflammatory signals toward a younger pattern and kept the cells as fibroblasts rather than turning on Yamanaka-style pluripotency. In aged mice, a liver-directed virus carrying SRSF1 slowed frailty and extended median lifespan by 14 percent compared with controls. The release does not state the sex of the mice. This is not a human treatment. Not medical advice.

Read at Nature Aging →♡ Save

• mice
• gene-expression
• lifespan
• longevity
• aging
• inflammation
• study